EMEA-001860-PIP03-16-M02

Key facts

Invented name
Emgality
Active substance
Galcanezumab
Therapeutic area
Neurology
Decision number
P/0111/2019
PIP number
EMEA-001860-PIP03-16-M02
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Prevention of migraine headaches
Route(s) of administration
Subcutaneous use
Contact for public enquiries
Eli Lilly and Company Limited

E-mail: eu_paediatric@lilly.com
Tel.: +44 1276483000

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating